Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13468751 | 0.79 | PTGS2 (0.49) | PTGS1PTGS2 | |
| SCHEMBL19667742 | 0.76 | LPL (0.40) | LPLLIPGROCK1P2RX7 | |
| SCHEMBL15335297 | 0.75 | LPL (0.39) | LPLLIPGROCK1P2RX7 | |
| SCHEMBL31394217 | 0.74 | LPL (0.38) | LPLLIPGROCK1P2RX7 | |
| SCHEMBL6691092 | 0.74 | LPL (0.50) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL10158678 | 0.73 | NOTUM (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL26153570 | 0.72 | LPL (0.48) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL30748977 | 0.72 | LPL (0.36) | LPLLIPGROCK1P2RX7 | |
| SCHEMBL15634931 | 0.72 | LPL (0.36) | LPLLIPGROCK1P2RX7 | |
| SCHEMBL18530194 | 0.72 | LPL (0.36) | LPLLIPGROCK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114364675-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | LPL 4724/4885LIPG 4506/4885ROCK1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.